
    
      Primary Objective:

      This study will evaluate the safety and efficacy of two different PEG-interferon and
      Ribavirin regimens in patients who have not previously been treated for Hepatitis C. Patients
      have an equal chance to assignment to one of two treatment arms:

      Treatment Arm A:

      PEG-interferon 1.5 mcg/kg2 QW + Ribavirin 800 mg/day

      OR

      Treatment Arm B:

      PEG-interferon 1.5mcg/kg2 QW + Ribavirin 800 to 1400 mg/day

      Arm A & Arm B: Duration of treatment will be 48 weeks for genotype 1 patients and 24 or 48
      weeks for genotype 2 or 3 patients.
    
  